Document:

<PAGE>   1
                                                                   EXHIBIT 10.36

                       WAIVER OF CONTRACTUAL RESTRICTIONS

        This Waiver (this "Waiver") is entered into on February 6, 2001 by and
between La Jolla Pharmaceutical Company ("LJP") and Abbott Laboratories
("Abbott").

                                    RECITALS

        WHEREAS, LJP and Abbott entered into that certain Stock Purchase
Agreement, dated December 23, 1996 (the "Agreement");

        WHEREAS, Abbott acquired certain shares of common stock of LJP (the
"Shares") under the Agreement;

        WHEREAS, Abbott desires to sell the Shares from time to time without the
restrictions currently imposed by the Agreement; and

        WHEREAS, Abbott and LJP mutually desire to terminate certain rights that
each has under the Agreement.

        NOW, THEREFORE, in consideration of the representations, warranties and
covenants herein contained, the parties hereto hereby agree as follows:

                                   AGREEMENT

        1. Waiver of LJP. LJP hereby fully, finally and irrevocably waives the
following:

           (a) the restrictions on transfer contained in Section 5(b) of the
Agreement;

           (b) its right of first refusal contained in Section 5(c) of the
Agreement; and

           (c) Abbott's obligation to cause certain subsequent purchasers of the
Shares to be bound by the terms of the Agreement contained in Section 5(e) of
the Agreement.

        2. Reliance by Abbott. LJP agrees that Abbott may rely on this Waiver in
disposing of the Shares without regard to the sale and transfer restrictions
contained in the Agreement and without offering LJP the opportunity to purchase
the Shares, as previously required by the Agreement. Notwithstanding the
foregoing, if and to the extent that it is reasonably practicable, Abbott will
give LJP 48 hours written notice prior to selling a significant amount of its
Shares.

        3. Waiver of Abbott. Abbott hereby fully, finally and irrevocably waives
the following:

           (a) its right to receive reports that LJP periodically files with the
Securities and Exchange Commission contained in Section 5(a) of the Agreement;

           (b) LJP's Nasdaq obligations contained in Section 5(f) of the
Agreement;

                                       1
<PAGE>   2
           (c) its right of first refusal on new issuances of securities of the
LJP contained in Section 5(h) of the Agreement; and

           (d) its rights contained in Section 6 of the Agreement, including,
without limitation, its demand registration rights under Section 6(a) of the
Agreement, if any currently exist, and its incidental registration rights under
Section 6(c) of the Agreement.

        4. Release of Abbott. LJP, for itself and its agents, successors and
assigns, does hereby forever release and discharge Abbott, and any of its past
or present agents, employees, officers, directors, attorneys from causes of
action, losses, promises, damages, costs, expenses, liabilities and demands of
whatsoever character, nature and kind, known or unknown, suspected or
unsuspected, fixed or contingent, arising out of or in any way related to the
actions, conduct, omissions or events related to or arising out of this Waiver.

        5. Release of the LJP. Abbott, for itself and its agents, successors and
assigns, does hereby forever release and discharge LJP, and any of its past or
present agents, employees, officers, directors, attorneys from causes of action,
losses, promises, damages, costs, expenses, liabilities and demands of
whatsoever character, nature and kind, known or unknown, suspected or
unsuspected, fixed or contingent, arising out of or in any way related to the
actions, conduct, omissions or events related to or arising out of this Waiver.

        6. Waiver of Section 1542 of the Civil Code. The parties specifically
understand, acknowledge and agree that the releases enumerated in Sections 4 and
5 of this Waiver are a full and final releases, which shall be effective as a
bar to all actions, claims, counterclaims, obligations, causes of action,
losses, promises, damages, costs, expenses, liabilities and demands of
whatsoever character, nature and kind, known and unknown, suspected or
unsuspected, fixed or contingent, hereinabove specified to be so barred. The
parties, having been fully advised by their respective counsel, hereby expressly
and voluntarily waive all rights or benefits that they and each of them might
otherwise have under the provisions of Section 1542 of the Civil Code of the
State of California, which provides as follows, and under all federal, state
and/or common law statutes or principles of similar effect:

           A general release does not extend to claims which the creditor does
           not know or suspect to exist in his favor at the time of executing
           the release, which if known by him must have materially affected his
           settlement with the debtor.

        7. Counterparts. This Waiver may be executed in any number of
counterparts, each of which will be deemed an original, but all of which
together will constitute one instrument, and signatures transmitted
electronically or by facsimile will be deemed original signatures.

                                       2
<PAGE>   3
        IN, WITNESS WHEREOF, LJP and Abbott each have caused this Waiver to be
executed by a duly authorized officer as of the date first written above

                                   LA JOLLA PHARMACEUTICAL COMPANY:

                                   /s/ Steven B. Engle
                                   -------------------------------
                                   Steven B. Engle,
                                   Chief Executive Officer

                                   ABBOTT LABORATORIES:

                                   /s/ GW Linder
                                   -------------------------------
                                   Greg W. Linder
                                   Vice President and Treasurer

                                       3<PAGE>   1
*** Certain information (indicated by an asterisk) has been omitted from this
document pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

                                                                   EXHIBIT 10.19

                                  AMENDMENT 1

To the Distribution and License Agreement, dated July 19,1999 ("Agreement"), by
and between Laboratoires Fournier S.A. ("Fournier") and Women First Healthcare
Inc. ("WFHC") is made this 3rd day of November, 2000.

WHEREAS, the parties wish to amend certain provisions of the Agreement.

NOW THEREFORE, in consideration of the premises and of the covenants herein
contained, the parties hereto mutually agree to amend the Agreement as follows :

1.  Article 1.5 of the Agreement is deleted in its entirety.

2.  The following sentence is added to the end of Article 1.14 of the Agreement:

        "Notwithstanding the foregoing, in the case of a Managed Care
        Organization ("MCO") or Group Purchasing Organization ("GPO") contract
        (the financial terms of which are provided to Fournier for review), the
        aggregate of any deductions made pursuant to subparagraphs (a) and (b)
        above shall never exceed *** of such gross invoiced sales on an
        annual basis under such MCO or GPO contract."

3. The following sentence is added to the end of Article 3.2 of the Agreement:

        "WFHC may defer the payment of the $350,000 set forth in this Article
        3.2(d) until November 15, 2001, provided that each of the following
        occurs (i) WFHC submits to Fournier the final protocol for at least one
        phase IV clinical study prior to November 20, 2000, (ii) Fournier
        approves of such protocol, in its discretion, in writing, and (iii) WFHC
        implements such phase IV clinical study prior to January 15, 2001. In
        the event of failure of any of these conditions, then the $350,000 shall
        become immediately due and payable. Upon receipt by Fournier of the
        final protocol from WFHC relating to such study, Fournier will use its
        reasonable efforts to notify WFHC of its approval of such protocol or
        any concerns it may have relating to such protocol within fifteen (15)
        business days of Fournier's receipt thereof."

4.  The following provision is added to end of Article 3.3 of the Agreement:

        "3.3(iii) in the case of Product sales under MCO and GPO contracts as
        set forth herein, WFHC shall pay to Fournier (in lieu of the royalty and
        supply prices identified in Article 3.3(i) and 3.3(ii)) the following:

                (a)     in further consideration of the license granted to WFHC
                        herein pay to Fournier a royalty quarterly during the
                        Term equal to the greater of (i) *** of Net
                        Sales under MCO and GPO contracts, or (ii) the floor
                        royalty for MCOs and GPOs equal to *** per patch for
                        any dosage form, based on the Product sold during the
                        applicable quarter (including a patent royalty equal to
                        *** of Net Sales under MCO and GPO
                        contracts), and

                (b)     in consideration of the supply of Product pay to
                        Fournier the Shipping Costs and the greater of (i)
                        *** of Net Sales of the Product sold under MCO
                        and GPO contracts or (ii) the floor price for MCOs and
                        GPOs equal to *** per patch for any dosage form.

<PAGE>   2

        3.3(iv) in consideration for the supply of Product which is used by WFHC
        solely for the performance of Phase IV clinical studies in accordance
        with Article 7.1, pay to Fournier *** plus Shipping Costs per patch
        for any dosage form. In the event that WFHC uses Product (which has
        already been purchased in accordance with the terms of this Agreement)
        for the performance of such Phase IV clinical studies, then Fournier
        shall issue to WFHC a credit for the difference between (i) the price
        actually paid for such Product on a per patch basis, and (ii)***
        per patch ("Credit"), provided that WFHC submits to Fournier written
        documentation showing that such Product was actually used in the
        performance of such Phase IV clinical study. The parties agree that the
        Credit, if any, shall be applied to the deferred payment of $ described
        in Article 3.2(d)."

5. The first three (3) sentences of Article 3.6 of the Agreement are deleted in
their entirety and replaced by the following:

        "3.6 Samples. Fournier shall supply WFHC with a reasonable quantity of
        Samples (to be agreed upon by the parties in good faith) for promotional
        purposes, in the form of individual sachets containing one patch, for a
        price of *** per sachet (one patch), plus Shipping Costs and (as the
        case may be) final packaging costs, C.I.F. WFHC's distribution facility
        in Newark, Delaware, for the 25micrograms, 37.5micrograms and
        50micrograms dosage forms. The Sample price set forth herein shall only
        apply to those quantities of Samples, which do not exceed (i) the
        quantities identified on Appendix 1 (for Sales Year 2 and Sales Year 3),
        and (ii) the quantity identified for Sales Year 3 for any single Sales
        Year thereafter. Fournier shall also supply WFHC with a reasonable
        quantity of Samples of the 75micrograms and 100micrograms dosage forms
        for distribution to hospitals for promotional purposes, in the form of
        individual sachets containing one patch, for a price of *** per sachet
        (one patch), plus Shipping Costs and (as the case may be) final
        packaging costs, C.I.F. WFHC's distribution facility in Newark,
        Delaware, provided that WFHC can provide written justification, using
        the call records, that such Samples were actually distributed to
        hospitals."

6.  Article 3.7 of the Agreement is deleted in its entirety and replaced by the
following:

        "3.7 Forecasts and Orders. WFHC shall provide Fournier a written twelve
        (12) month rolling forecast at least ten (10) days prior to the first
        day of each calendar month ("M"), such forecast to specify the requested
        quantity and shipment dates for each Product form, including Samples and
        Placebo Samples. Each forecast shall be binding upon WFHC with respect
        to orders forecast for the Product (including Samples and Placebo
        Samples) to be delivered in the calendar months M+3, M+4 and M+5. WFHC
        shall issue firm purchase orders for its requirements of Product not
        less than ninety (90) days prior to the date of requested shipment.
        Fournier shall not be obligated to ship a Product by the shipment date
        set forth in any purchase order which is received by Fournier less than
        ninety (90) days prior to such shipment date. Any firm purchase order
        for each Product form, Sample and Placebo Sample shall amount to the
        Full Lot (as defined below) for any single dosage form or Placebo
        Sample. A Full Lot (except for Placebo Samples) may be comprised of
        different dosage forms provided that such dosage forms constitute a Full
        Lot on a percent basis, and further provided that each dosage form shall
        equal, at a minimum, one-tenth of a Full Lot for such dosage form. By
        way of example only, WFHC would satisfy this provision under any of the
        following scenarios: (i) a purchase order for 255,000 patches of
        50micrograms Product, (ii) a purchase order for 250,000 patches of
        25micrograms Product, plus 200,000 patches of 25micrograms Samples, or
        (iii) a purchase order for 90,000 patches of 25micrograms Product (1/5
        Full Lot for 25micrograms), plus 96,000 patches of 100micrograms Product
        (4/5 Full Lot for 100micrograms). Notwithstanding the foregoing, for the
        Placebo Samples only, a Full Lot may never be less than 100,000 patches.

        *** Certain information (indicated by an asterisk) has been omitted from
        this document pursuant to a request for confidential treatment. The
        omitted material has been filed separately with the Securities and
        Exchange Commission.
<PAGE>   3

<TABLE>
<CAPTION>
        The term "Full Lot" as used in this Section shall mean:
        ------------------------------------------------------
<S>                                                                    <C>
        -for the 25microgram dosage form of Product/Sample             *** patches
        -for the 37.5microgram dosage form of the Product/Sample       *** patches
        -for the 50microgram dosage form of Product/Sample             *** patches
        -for the 75microgram dosage form of Product/Sample             *** patches
        -for the 100microgram dosage form of Product/Sample            *** patches
        -for the Placebo Sample                                        *** patches
</TABLE>

        Fournier may by not more than 10% adjust the amounts of Product to be
        delivered, so that such amounts correspond with one manufacturing run or
        an integral number thereof. None of WFHC's standard terms of purchase
        and none of Fournier's standard terms of sale or supply shall govern any
        supply of Product (including Samples and Placebo Samples) under this
        Agreement, nor shall such terms supplement or modify any terms and
        conditions thereof, despite possible inclusion in any purchase order,
        order confirmation or other document."

7.  Except as set forth herein, the Agreement shall remain unchanged.

8. All defined terms in this Amendment 1 which are included in the Agreement
shall have the same meaning as set forth in the Agreement.

9. In the event of a conflict between the Agreement and this Amendment 1, this
Amendment 1 shall control.

IN WITNESS WHEREOF, the parties have executed this Amendment 1 as of the date
first set forth above.

LABORATOIRES FOURNIER S.A.                WOMEN FIRST HEALTHCARE INC.
--------------------------                ---------------------------

By:                                       By:

Title:                                    Title:

*** Certain information (indicated by an asterisk) has been omitted from this
document pursuant to a request for confidential treatment. The omitted material
has been filed separately with the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}]]